Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ASLAN Pharmaceuticals Limited

Market Cap 1.7M 53.68M 1.47M 1.36M 1.28M 2.39M 160M 2.42M 16.14M 6.26M 78.78M 6.37M 6.23M 272M P/E 2022
-0.49x
P/E 2023 -0.19x
Enterprise Value 7.27M 230M 6.32M 5.81M 5.47M 10.25M 687M 10.36M 69.12M 26.8M 338M 27.28M 26.7M 1.17B EV / Sales 2022
-
EV / Sales 2023 1,189,813x
Free-Float
99%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 53 2010-12-31
Director of Finance/CFO 47 2010-10-31
Chief Tech/Sci/R&D Officer - 2022-03-14
Director TitleAgeSince
Chairman 53 2014-05-31
Chairman 66 2019-07-25
Director/Board Member 67 2021-02-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.92% - - 1.7M
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.04%+6.61%-13.27%-18.06% 22.63B
+3.07%-0.60%-3.09%+392.25% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
+0.65%-1.04%+25.60%+174.70% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.27%+4.82%+75.35%+104.79% 11.56B
Average +0.93%+0.18%+25.16%+91.05% 23.3B
Weighted average by Cap. +1.53%+0.18%+31.63%+90.69%

Financials

2022 2023
Net sales - 12 379.61 10.43 9.59 9.02 16.92 1.13K 17.1 114.1 44.24 557.1 45.03 44.07 1.93K
Net income -51.38M -1.63B -44.65M -41.07M -38.64M -72.44M -4.86B -73.22M -489M -189M -2.39B -193M -189M -8.25B -44.22M -1.4B -38.43M -35.35M -33.25M -62.34M -4.18B -63.01M -420M -163M -2.05B -166M -162M -7.1B
Net Debt -19.28M -610M -16.76M -15.41M -14.5M -27.18M -1.82B -27.48M -183M -71.09M -895M -72.36M -70.81M -3.1B 5.57M 176M 4.84M 4.45M 4.19M 7.86M 527M 7.94M 52.99M 20.55M 259M 20.92M 20.47M 895M
Logo ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!